Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: avgoustidis n. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A, Papalopoulos I, Gergianaki I, Spyrou G, Erden A, Rapsomaniki P, Terizaki M, Avgoustidis N, Repa A, Kougkas N, Bertsias G, Boumpas DT, Sidiropoulos PI. Fanouriakis A, et al. Among authors: avgoustidis n. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):806-813. Epub 2018 Feb 28. Clin Exp Rheumatol. 2018. PMID: 29533750
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, Pitsigavdaki S, Kalogiannaki E, Terizaki M, Bertsias G, Sidiropoulos P. Flouri I, et al. Among authors: avgoustidis n. Rheumatol Int. 2024 Feb;44(2):249-261. doi: 10.1007/s00296-023-05455-7. Epub 2023 Oct 10. Rheumatol Int. 2024. PMID: 37815625 Free PMC article.
Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus.
Adamichou C, Nikolopoulos D, Papastefanakis E, Kalogiannaki E, Gergianaki I, Kountouri A, Repa A, Avgoustidis N, Kougkas N, Sidiropoulos P, Fanouriakis A, Bertsias G. Adamichou C, et al. Among authors: avgoustidis n. Mediterr J Rheumatol. 2018 Dec 18;29(4):232-235. doi: 10.31138/mjr.29.4.232. eCollection 2018 Dec. Mediterr J Rheumatol. 2018. PMID: 32185334 Free PMC article.
The value of the 2011 ASAS classification criteria in patients with Spondyloarthritis and the prognosis of non-radiographic axial Spondyloarthritis: data from a large cohort of a tertiary referral hospital.
Kougkas N, Avgoustidis N, Repa A, Bertsias G, Eskitzis A, Sidiropoulos P. Kougkas N, et al. Among authors: avgoustidis n. Mediterr J Rheumatol. 2019 Mar 28;30(1):51-53. doi: 10.31138/mjr.30.1.51. eCollection 2019 Mar. Mediterr J Rheumatol. 2019. PMID: 32185344 Free PMC article.
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E, Bertsias G, Flouri I, Sidiropoulos P. Bertsias A, et al. Among authors: avgoustidis n. Arthritis Res Ther. 2022 Jun 2;24(1):132. doi: 10.1186/s13075-022-02826-6. Arthritis Res Ther. 2022. PMID: 35655317 Free PMC article.
23 results